Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) will reach no more than half of eligible overweight and obese patients globally, the chief executive of Eli Lilly said last week, citing structural barriers in health care systems that no market expansion can fully overcome.

David Ricks, speaking at a conference, told reporters that systemic constraints will cap adoption of GLP-1 drugs at roughly 40 to 50 percent of the population that could clinically benefit. “It’s never going to be a hundred,” Ricks said. “For institutional reasons in health care and some other complexities in managing health, it’s never going to be that high.” The analogy he offered was sobering: statins, among the most widely prescribed cholesterol-lowering agents in clinical history, reach between 40 and 50 percent of patients who have a clear indication for them. “Between 40 and 50% of people who should be on them, are on them. I think of that as maybe a ceiling,” he said.

That framing carries weight in the oncology-adjacent metabolic disease space. Obesity is a recognized risk factor for at least 13 cancer types, according to the National Cancer Institute, including endometrial, colorectal, pancreatic, and postmenopausal breast cancers. Reduced GLP-1 penetration doesn’t just limit cardiovascular or metabolic benefits. It limits a meaningful upstream intervention against obesity-driven malignancy risk.

The global market for GLP-1 drugs is projected by analysts to exceed $100 billion annually within the next decade, with Eli Lilly and Novo Nordisk competing for dominant market share. Yet current utilization stands at roughly 1 in 10 overweight or obese patients. That gap, between 10 percent current use and a projected ceiling of 50 percent, defines the realistic opportunity window, and it’s considerably narrower than the market projections alone suggest.

For clinicians managing patients with obesity-related comorbidities, the implications are direct.

Insurance coverage remains uneven. Medicare, the primary payer for the population at highest cancer risk, has historically restricted GLP-1 coverage for weight management despite recent policy movement. The Centers for Medicare and Medicaid Services has not yet established broad Part D coverage for GLP-1 drugs prescribed solely for obesity in the general Medicare population, though the Biden administration’s 2025 proposed rule gestured toward expansion. Whether current federal priorities will advance or retract that coverage pathway is unclear.

The cost barrier is not theoretical. List prices for semaglutide and tirzepatide remain above $800 per month in many U.S. markets without manufacturer assistance, placing them out of reach for a substantial share of patients who don’t meet insurer criteria for reimbursement. In Pacific Islander and Native Hawaiian populations, where obesity prevalence is disproportionately high and rates of obesity-associated cancers including endometrial and colorectal malignancy are elevated relative to national averages, the access gap is clinically consequential and demands specific attention from Hawaii-based practitioners.

Ricks didn’t frame the ceiling as a failure. He framed it as a structural reality analogous to what the pharmaceutical industry observed with statins over several decades.

That analogy deserves scrutiny. Statins became generically available after patent expiration, dramatically reducing cost and expanding access. GLP-1 drugs, which are biologics or complex small molecules depending on the agent, don’t follow the same generic pathway with the same ease. Biosimilar development for semaglutide is underway, and STAT News has tracked the competitive and regulatory dynamics shaping that pipeline, but timelines remain uncertain and price reductions may be less dramatic than those seen with traditional generic entry. The statin comparison is instructive but not perfectly predictive.

From a health policy standpoint, the 50 percent ceiling scenario has concrete implications for population-level disease burden. If half of eligible patients can’t get or won’t sustain GLP-1 therapy, the public health gains from these agents in reducing obesity-related cancer incidence will be partial at best. Trial data from the SELECT cardiovascular outcomes trial, which enrolled patients with established cardiovascular disease, showed that semaglutide 2.4 mg produced a 20 percent relative risk reduction in major adverse cardiovascular events over a mean follow-up of 34.2 months (hazard ratio 0.80; 95% confidence interval, 0.72 to 0.90; p less than 0.001). Whether comparable risk reduction applies to cancer-specific outcomes awaits further data, but the biological plausibility of GLP-1 agents attenuating obesity-driven tumor microenvironment signaling is an active area of research.

On a separate but related regulatory front, the U.S. Department of Labor proposed a rule in January 2026 requiring pharmacy benefit managers (PBMs) to disclose a wide range of drug pricing information to employers and face broader audit exposure. The public comment period closed last week. More than 500 comment letters were submitted, reflecting predictable fault lines.

PBMs and health insurers resisted. Mark Cuban’s pharmacy operation and others in the business community that want PBM intermediaries held more accountable voiced support. Drug manufacturers, for their part, expressed support for PBM transparency requirements while pushing back on provisions that would require disclosure of manufacturer-level drug pricing data.

The opposition is substantial.

It’s well-organized. A coalition of lobbyists representing both PBMs and insurers has mounted resistance that observers describe as coordinated and aggressive.

For oncology specifically, the PBM transparency debate is not peripheral. Specialty oncology drugs, including many oral targeted therapies and the growing class of antibody-drug conjugates, move through PBM formulary structures that shape patient cost-sharing in ways that are currently difficult for employers, patients, or independent researchers to audit. A clinician recommending a first-line tyrosine kinase inhibitor can’t tell a patient with any confidence what they’ll pay at the pharmacy counter, because that number depends on rebate arrangements, formulary tier placements, and copay accumulator policies that aren’t publicly disclosed.

The proposed Labor Department rule would, if finalized, require PBMs to produce data that could let employers and auditors evaluate whether rebate revenues are being passed through to plan sponsors or captured at the PBM level. For cancer drug affordability, that visibility could matter. Oral oncolytic drugs represent some of the highest-cost agents in the specialty tier, and PBM formulary decisions about these drugs directly affect adherence. Adherence directly affects outcomes.

In the Hawaii context, where a considerable share of the commercially insured population is covered through employer-sponsored plans governed by federal ERISA rules, the Labor Department’s jurisdiction over PBMs is particularly relevant. State insurance regulations don’t reach self-funded employer plans. Federal action is one of the few levers available to change pricing transparency at the PBM level for that population.

The Pacific Islander and Native Hawaiian patient populations that Hawaii Medical Journal covers are disproportionately represented among the underinsured and among patients navigating high-deductible employer plans. Both the GLP-1 access ceiling and the PBM transparency debate land differently in this region than they do in markets with higher median household incomes and denser health system infrastructure. The 50 percent ceiling Ricks described reflects a national average. In Hawaii’s lower-income zip codes and neighbor island communities, the realistic ceiling may be considerably lower than that.

Whether the Labor Department rule survives the current regulatory environment intact is uncertain. Comment letters opposing the rule from PBM and insurer lobbyists tend to raise legal challenges about data protection, administrative burden, and statutory authority. Those arguments have succeeded in delaying or weakening similar transparency rules in the past.

What isn’t uncertain is the clinical reality that drug pricing opacity and access barriers are not abstract policy concerns. They produce measurable differences in prescription fill rates, treatment discontinuation, and ultimately in the survival outcomes that define whether a drug’s trial efficacy translates to population-level benefit. A GLP-1 drug that demonstrated a 15 percent reduction in obesity-associated cancer risk in a well-designed randomized controlled trial would generate no meaningful population-level impact if only 10 percent of eligible patients can access it.

The Ricks ceiling projection and the PBM transparency battle are different stories on the surface. At the level of patient access, they describe the same problem.